


# GETTING THE WORLD VACCINATED AGAINST COVID-19

MAY 2022  
STATISTICS UPDATE




## VACCINE PRODUCTION DEMAND DROPS AND VACCINATION ROLLOUTS SLOW DOWN GLOBALLY

### COVID-19 vaccine production consistently outpaces doses administered




### COVID-19 vaccines administered (6-month rolling average)




## THERE ARE SIGNIFICANT LEVELS COVID-19 VACCINE STOCKS COVERING ALL REGIONS


### COVID-19 vaccines donated and administered ("vaccines out")



### COVID-19 vaccines received ("vaccines in")




### Excess stocks of COVID-19 vaccines



The number of produced COVID-19 vaccines has consistently outpaced the number of vaccines administered, demonstrating that production is not the bottleneck. Vaccination rates have dropped since November 2021, reducing vaccine demand. As a result, COVID-19 vaccine production is levelling off. Currently 2.1 billion excess COVID-19 vaccines are available, and – in compliance with shelf-life expiry – at risk of being wasted and destroyed. Low-income countries still face several challenges to vaccinations: healthcare absorptive capacities, vaccine roll-out problems, and low levels of vaccine acceptance.

## VACCINE DONATIONS AND DELIVERIES ARE LEVELLING OFF BECAUSE RECEIVING COUNTRIES ARE INCREASINGLY REQUESTING TO POSTPONE OR CANCEL VACCINE DELIVERIES

### Bilateral and COVAX supply and donations of COVID-19 vaccines to LMIC/LIC



### COVID-19 vaccine postponements, cancellations and waste

- 01 Dec 2021** South African health officials turn away Pfizer/BioNTech and J&J vaccine shipments (NY times)
- 07 Dec 2021** 1 million COVID-19 vaccine doses expired in Nigeria (Reuters)
- 24 Dec 2021** Namibia destroys 150,000 vaccines (CBC)
- 13 Jan 2022** UNICEF shows that 681 million vaccines are unused in 90 poorer nations around the world (Reuters)
- 22 Feb 2022** African CDC asks world to pause COVID-19 vaccine donations (Politico)
- 26 Apr 2022** Serum Institute of India (SII) stops production of AZ vaccine (Brussels Times)
- 27 Apr 2022** Open and closed vial COVID-19 vaccine wastage rates reached 30% in some countries (BMJ Global Health, 2022)
- 05 May 2022** Aspen (S. Africa) to reduce COVID vaccine production capacity by 50% (Reuters)
- 22 May 2022** 2.1 billion COVID-19 unused vaccines are at risk of being wasted and destroyed (Airfinity)

COVAX has indicated that it has sufficient levels of vaccine supplies to meet COVID-19 vaccine demand. This is reflected in its donations having levelled off, which has also been the case for bilateral donations, due to dwindling demand for COVID-19 vaccines from lower middle-income countries (LMIC) and low-income countries (LIC).

# GETTING THE WORLD VACCINATED AGAINST COVID-19

MAY 2022  
STATISTICS UPDATE




## INDUSTRY DRIVES R&D AND COVID-19 RESEARCH CONTINUES APACE, MAKING INTELLECTUAL PROPERTY PROTECTION VITAL

### Total COVID-19 vaccine investments and pipeline

- Only **5.3%** of researched vaccines and **2.0%** of treatments have been **approved**.
- New vaccines and treatments **enhance protection** against new COVID-19 variants and **boost price competition**.
- Up to **€ 38.4 bn** has been invested.
- 75%** of investments are borne by the **industry** (large biopharmaceutical companies and SME biotech companies).
- 52% to 66%** of investments still have to be made.


Source: Airfinity (5 May 2022), EPO (2021)

### COVID-19 vaccines pipeline



Source: Airfinity (5 May 2022)


### COVID-19 Treatments pipeline




Source: Airfinity (5 May 2022)

## A COVID-19 TRIPS WAIVER UNDERMINES GLOBAL HEALTH SECURITY, DAMAGING R&D FOR CURRENT AND FUTURE PANDEMICS, AND HURTING INDUSTRIAL COMPETITIVENESS AND GROWTH IN THE EU, UK, US AND KEY PARTNERS


### Share of patent applications for (later) COVID-19 use at EPO\* (2015-2020)




### A waiver would destabilise voluntary licencing agreements



### Impact of 3-year COVID-19 waiver on pharmaceutical industry R&D




### European SMEs would be impacted by a TRIPS waiver



87% of all COVID-19 vaccine focused patent applications stem from the US and Europe. Weakening IP undermines the legal basis for the 372 voluntary licensing agreements for COVID-19 vaccines and 155 agreements for therapeutics. Pharmaceutical investments could go down by €43 bn. 94% of this decrease will be borne by HIC and UMIC, like the EU and US.

## THREE PRIORITIES TO URGENTLY INCREASE ACCESS TO COVID-19 VACCINES



CONTRIBUTE TO EQUITABLE DISTRIBUTION



STEP UP SUPPORT FOR COUNTRY READINESS



CONTINUE TO DRIVE INNOVATION